Medical Condition News

RSS

ZEVALIN treatment for Non-Hodgkin lymphoma becomes simpler with removal of bioscan requirement

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, received approval from the U.S. Food and Drug Administration (FDA) on November 18, 2011 to remove the pre-treatment biodistribution evaluation requirement using Indium-111 ZEVALIN imaging dose followed by a gamma scan before administering the ZEVALIN therapeutic dose.

21 Nov 2011

Positive preliminary results from Alnylam's ALN-TTR01 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today positive preliminary results from its Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR).

21 Nov 2011

Adeona to develop and commercialize DNA-based therapeutic for PAH using Intrexon technology

Adeona Pharmaceuticals, Inc., and the Human Therapeutics Division of Intrexon Corporation, announced today the formation of a global exclusive channel collaboration through which Adeona intends to develop and commercialize a DNA-based therapeutic using Intrexon's UltraVector platform and RheoSwitch Therapeutic System for the treatment of pulmonary arterial hypertension (PAH).

21 Nov 2011

Selecta commences SEL-068 Phase 1 clinical trial for smoking cessation and relapse prevention

Selecta Biosciences, Inc., a biopharmaceutical company developing a new class of synthetic vaccines and immunotherapies, today announced that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacodynamic profile of SEL-068, a nicotine vaccine candidate for smoking cessation and relapse prevention.

21 Nov 2011

Cancer Research UK initiates recruitment for Stratified Medicine Programme

Cancer Research UK has started recruiting patients for a pioneering initiative to demonstrate how genetic tests could be used within the NHS to help match cancer patients to the most appropriate treatment, while building a database of information for research into new targeted therapies.

21 Nov 2011

ICON selected as CRO for Tasly's Dantonic pill global Phase III studies for chronic stable angina pectoris

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by Tasly Pharmaceuticals for the company's global Phase III T89 trial. T89, also known as Dantonic pill, aims to become the first traditional Chinese medicine to receive FDA approval in the United States.

21 Nov 2011

New blood pressure remote monitoring program for Stamford employees, families

Stamford Hospital has launched a new blood pressure remote monitoring program for its employees and their families in order to detect risk factors for heart disease while helping to improve their overall health.

21 Nov 2011

EMA validates Pfizer's Market Authorisation Application for tofacitinib to treat rheumatoid arthritis

Pfizer Inc. announced today that its Market Authorisation Application for tofacitinib (development code CP-690,550), a novel, oral JAK inhibitor being studied for the treatment of moderate-to-severe active rheumatoid arthritis (RA), has been validated by the European Medicines Agency (EMA).

21 Nov 2011

South Asian cardiac patients three times as likely to require repeat treatment following PCI

South Asian patients with coronary artery disease were almost three times as likely to be readmitted to hospital for further interventional treatment to arterial plaque than their White European counterparts, according to research in the December issue of IJCP, the International Journal of Clinical Practice.

21 Nov 2011

New method for counting molecules

Researchers at the Swedish medical university Karolinska Institutet have developed a new method for counting molecules.

21 Nov 2011

Convergence commences CNV2197944 multiple ascending dose Phase I study for chronic pain

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announces that the multiple ascending dose Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated.

21 Nov 2011

Yeast protein in vaccines for more efficient immune response

To enhance the efficiency of vaccines, researchers at the division of chemical technology, Luleå University of Technolgy (LTU) have in co-operation with Karolinska Institute and Recopharma AB developed a strategy with the aim of directing vaccine components to critical parts of the immune system so that a more efficient immune response can be generated. The researchers have used a special type of protein produced in yeast.

21 Nov 2011

Retina Implant scientific advisory board approves multi-center phase of second human clinical trial

Retina Implant AG, the leading developer of subretinal implants for retinitis pigmentosa patients, today announced that its scientific advisory board is in full support of beginning the multi-center phase of the Company's second human clinical trial. The trial, which began in Tuebingen, Germany in 2010, will be expanded across Europe in five new sites, including two additional locations in Germany, Oxford, London and Budapest.

21 Nov 2011

American high school students earn top honors for liver disease and brain injury research

The shortlist of contenders for the highest science honor awarded to American high school students narrowed tonight as the winners of the Siemens Competition in Math, Science & Technology Region 3 Finals were announced.

21 Nov 2011

New material emits long-lasting, near-infrared glow after sunlight exposure

Materials that emit visible light after being exposed to sunlight are commonplace and can be found in everything from emergency signage to glow-in-the-dark stickers. But until now, scientists have had little success creating materials that emit light in the near-infrared range, a portion of the spectrum that only can be seen with the aid of night vision devices.

21 Nov 2011

Scientists unravel how brain combines different sensory cues to make sense of our world

The human brain is bombarded with a cacophony of information from the eyes, ears, nose, mouth and skin. Now a team of scientists at the University of Rochester, Washington University in St. Louis, and Baylor College of Medicine has unraveled how the brain manages to process those complex, rapidly changing, and often conflicting sensory signals to make sense of our world.

21 Nov 2011

Promising results from dexpramipexole phase 2 trial on ALS

Treatment with dexpramipexole - a novel drug believed to prevent dysfunction of mitochondria, the subcellular structures that provide most of a cell's energy - appears to slow symptom progression in the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Promising results of a phase 2 trial of dexpramipexole are receiving advance online publication in Nature Medicine.

20 Nov 2011

Scientists show that the sense of smell can be improved

In a new study scientists at NYU Langone Medical Center have shown that the sense of smell can be improved. The new findings, published online November 20, 2011, in Nature Neuroscience, suggest possible ways to reverse the loss of smell due to aging or disease.

20 Nov 2011

Two genetic rearrangements may trigger 5 to 7% of breast cancers

Researchers at the University of Michigan Comprehensive Cancer Center have discovered two cancer-spurring gene rearrangements that may trigger 5 to 7 percent of all breast cancers.

20 Nov 2011

Switching or adding antidepressants does not exacerbate side effects

Patients with major depression who fail to see improvement after taking an antidepressant often have their initial medication switched or combined with a second drug. Many clinicians weigh the possibility of adverse side effects when deciding between strategies. New research in the latest issue of General Hospital Psychiatry now suggests one strategy may not be any more likely to be harmful than the other.

19 Nov 2011

Medical Condition News

ZEVALIN treatment for Non-Hodgkin lymphoma becomes simpler with removal of bioscan requirement

Positive preliminary results from Alnylam's ALN-TTR01 Phase I clinical trial for TTR-mediated amyloidosis

Adeona to develop and commercialize DNA-based therapeutic for PAH using Intrexon technology

Selecta commences SEL-068 Phase 1 clinical trial for smoking cessation and relapse prevention

Cancer Research UK initiates recruitment for Stratified Medicine Programme

ICON selected as CRO for Tasly's Dantonic pill global Phase III studies for chronic stable angina pectoris

New blood pressure remote monitoring program for Stamford employees, families

EMA validates Pfizer's Market Authorisation Application for tofacitinib to treat rheumatoid arthritis

South Asian cardiac patients three times as likely to require repeat treatment following PCI

New method for counting molecules

Convergence commences CNV2197944 multiple ascending dose Phase I study for chronic pain

Yeast protein in vaccines for more efficient immune response

Retina Implant scientific advisory board approves multi-center phase of second human clinical trial

American high school students earn top honors for liver disease and brain injury research

New material emits long-lasting, near-infrared glow after sunlight exposure

Scientists unravel how brain combines different sensory cues to make sense of our world

Promising results from dexpramipexole phase 2 trial on ALS

Scientists show that the sense of smell can be improved

Two genetic rearrangements may trigger 5 to 7% of breast cancers

Switching or adding antidepressants does not exacerbate side effects

This International Women’s Day, Meet the Scientist Changing Women’s Healthcare

Microphysiological systems in drug discovery

Considerations for taking ASO discovery programs into animal models

Latest News